Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Orally active TxA2 antagonist in clinical development at Zeria

Feb. 25, 1999

Four U.S. patents provide additional protection for Corvas's rNAP program

Feb. 24, 1999

Abciximab improves microvascular perfusion after stenting in acute myocardial infarction

Feb. 24, 1999

Activase for acute management of stroke approved in Canada

Feb. 22, 1999

Astra's P2T receptor antagonists offer significant potential as novel antithrombotics

Feb. 19, 1999

Boehringer Ingelheim researches thrombin inhibitors

Feb. 19, 1999

New series of anticoagulants for oral administration developed at Lilly

Feb. 18, 1999

Another European market opens up to desirudin

Feb. 18, 1999

New hemophilia treatment approved by Health Canada

Feb. 18, 1999

Lilly's new orally active anticoagulants

Feb. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...